Roles of Histone Acetylation Modifiers and Other Epigenetic Regulators in Vascular Calcification

Vascular calcification (VC) is characterized by calcium deposition inside arteries and is closely associated with the morbidity and mortality of atherosclerosis, chronic kidney disease, diabetes, and other cardiovascular diseases (CVDs). VC is now widely known to be an active process occurring in va...

Full description

Bibliographic Details
Main Authors: Duk-Hwa Kwon, Juhee Ryu, Young-Kook Kim, Hyun Kook
Format: Article
Language:English
Published: MDPI AG 2020-05-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:https://www.mdpi.com/1422-0067/21/9/3246
id doaj-b2dfb48e14144d7da853417c6232cebd
record_format Article
spelling doaj-b2dfb48e14144d7da853417c6232cebd2020-11-25T02:38:16ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-05-01213246324610.3390/ijms21093246Roles of Histone Acetylation Modifiers and Other Epigenetic Regulators in Vascular CalcificationDuk-Hwa Kwon0Juhee Ryu1Young-Kook Kim2Hyun Kook3Department of Pharmacology, Chonnam National University Medical School, Hwasun 58128, KoreaDepartment of Pharmacology, Chonnam National University Medical School, Hwasun 58128, KoreaDepartment of Biochemistry, Chonnam National University Medical School, Hwasun 58128, KoreaDepartment of Pharmacology, Chonnam National University Medical School, Hwasun 58128, KoreaVascular calcification (VC) is characterized by calcium deposition inside arteries and is closely associated with the morbidity and mortality of atherosclerosis, chronic kidney disease, diabetes, and other cardiovascular diseases (CVDs). VC is now widely known to be an active process occurring in vascular smooth muscle cells (VSMCs) involving multiple mechanisms and factors. These mechanisms share features with the process of bone formation, since the phenotype switching from the contractile to the osteochondrogenic phenotype also occurs in VSMCs during VC. In addition, VC can be regulated by epigenetic factors, including DNA methylation, histone modification, and noncoding RNAs. Although VC is commonly observed in patients with chronic kidney disease and CVD, specific drugs for VC have not been developed. Thus, discovering novel therapeutic targets may be necessary. In this review, we summarize the current experimental evidence regarding the role of epigenetic regulators including histone deacetylases and propose the therapeutic implication of these regulators in the treatment of VC.https://www.mdpi.com/1422-0067/21/9/3246histone deacetylasehistone modifiersepigenetic regulatorvascular calcificationvascular smooth muscle cellspost-translational modification
collection DOAJ
language English
format Article
sources DOAJ
author Duk-Hwa Kwon
Juhee Ryu
Young-Kook Kim
Hyun Kook
spellingShingle Duk-Hwa Kwon
Juhee Ryu
Young-Kook Kim
Hyun Kook
Roles of Histone Acetylation Modifiers and Other Epigenetic Regulators in Vascular Calcification
International Journal of Molecular Sciences
histone deacetylase
histone modifiers
epigenetic regulator
vascular calcification
vascular smooth muscle cells
post-translational modification
author_facet Duk-Hwa Kwon
Juhee Ryu
Young-Kook Kim
Hyun Kook
author_sort Duk-Hwa Kwon
title Roles of Histone Acetylation Modifiers and Other Epigenetic Regulators in Vascular Calcification
title_short Roles of Histone Acetylation Modifiers and Other Epigenetic Regulators in Vascular Calcification
title_full Roles of Histone Acetylation Modifiers and Other Epigenetic Regulators in Vascular Calcification
title_fullStr Roles of Histone Acetylation Modifiers and Other Epigenetic Regulators in Vascular Calcification
title_full_unstemmed Roles of Histone Acetylation Modifiers and Other Epigenetic Regulators in Vascular Calcification
title_sort roles of histone acetylation modifiers and other epigenetic regulators in vascular calcification
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1661-6596
1422-0067
publishDate 2020-05-01
description Vascular calcification (VC) is characterized by calcium deposition inside arteries and is closely associated with the morbidity and mortality of atherosclerosis, chronic kidney disease, diabetes, and other cardiovascular diseases (CVDs). VC is now widely known to be an active process occurring in vascular smooth muscle cells (VSMCs) involving multiple mechanisms and factors. These mechanisms share features with the process of bone formation, since the phenotype switching from the contractile to the osteochondrogenic phenotype also occurs in VSMCs during VC. In addition, VC can be regulated by epigenetic factors, including DNA methylation, histone modification, and noncoding RNAs. Although VC is commonly observed in patients with chronic kidney disease and CVD, specific drugs for VC have not been developed. Thus, discovering novel therapeutic targets may be necessary. In this review, we summarize the current experimental evidence regarding the role of epigenetic regulators including histone deacetylases and propose the therapeutic implication of these regulators in the treatment of VC.
topic histone deacetylase
histone modifiers
epigenetic regulator
vascular calcification
vascular smooth muscle cells
post-translational modification
url https://www.mdpi.com/1422-0067/21/9/3246
work_keys_str_mv AT dukhwakwon rolesofhistoneacetylationmodifiersandotherepigeneticregulatorsinvascularcalcification
AT juheeryu rolesofhistoneacetylationmodifiersandotherepigeneticregulatorsinvascularcalcification
AT youngkookkim rolesofhistoneacetylationmodifiersandotherepigeneticregulatorsinvascularcalcification
AT hyunkook rolesofhistoneacetylationmodifiersandotherepigeneticregulatorsinvascularcalcification
_version_ 1724791680983367680